Recurrent Pericarditis
10
5
6
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (10)
An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
Transition to KPL-387 Monotherapy Dosing & Administration Study
CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)
REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients
Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)
Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis
Therapy Management in Patients Treated With Anakinra Due to Recurrent Pericarditis
Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis
A Pilot Study of KPL-914 in Recurrent Pericarditis